新药研发商Zucara Therapeutics宣布完成2500万美元B轮融资-动脉网

Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing

CISION 等信源发布 2025-05-01 19:30



可切换为仅中文







- T1D Fund Joins Financing Syndicate -

- T1D基金加入融资财团 -

- Proceeds to Fund Remainder of Phase 2a 'ZONE' Trial and Nonclinical Development of a Once-Weekly Version of ZT-01 -

- 资金将用于完成第二阶段2a期“ZONE”试验的剩余部分以及ZT-01每周一次版本的非临床开发 -

TORONTO

多伦多

，

May 1, 2025

2025年5月1日

/PRNewswire/ - Zucara Therapeutics Inc., ('Zucara' or the 'Company') a diabetes life sciences company developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people with diabetes, today announced that it has completed the second and final closing of its .

/PRNewswire/ - Zucara Therapeutics Inc.（“Zucara”或“公司”）是一家开发ZT-01的糖尿病生命科学公司，ZT-01是首个用于预防糖尿病患者低血糖（低血糖水平）的每日一次治疗药物。该公司今天宣布已完成其第二轮也是最后一轮融资。

US$25 million

2500万美元

Series B Financing (the 'Financing').

B轮融资（“融资”）。

The T1D Fund: A Breakthrough T1D Venture and other new investors invested a combined

T1D基金：一家突破性的T1D风险投资公司及其他新投资者共同投资了

US$5 million

500万美元

to complete the Financing. As

完成融资。作为

previously announced

此前已宣布

, strategic investor, Sanofi, and existing investor, The Perceptive Xontogeny Venture Fund ('PXV Fund I'), invested a combined

，战略投资者赛诺菲（Sanofi）和现有投资者 The Perceptive Xontogeny Venture Fund（“PXV Fund I”）共同投资了

US$20 million

2000万美元

as part of the Financing's first closing.

作为融资第一期收盘的一部分。

'We are thrilled to close our Series B financing, which will enable us to complete our Phase 2a clinical trial and the nonclinical activities to support a once-weekly version of ZT-01,' said

“我们很高兴完成B轮融资，这将使我们能够完成2a期临床试验及支持ZT-01每周一次版本的非临床活动，”

Michael Midmer

迈克尔·米德默

, CEO of Zucara. 'As one of the largest disease-focused impact investing funds in the world, the T1D Fund focuses on funding therapies that have significant potential for clinical impact in Type 1 diabetes, so we are delighted to have their support.'

Zucara的首席执行官表示：“作为全球最大的疾病导向型影响力投资基金之一，1型糖尿病基金专注于资助在1型糖尿病领域具有显著临床影响潜力的疗法，因此我们非常高兴得到他们的支持。”

T1D Fund Managing Director,

T1D基金常务董事，

Sylvia Tobé

西尔维娅·托贝

, commented, 'Our investment builds on funding that our parent organization, Breakthrough T1D, previously granted to Zucara to support the discovery and clinical development of ZT-01. Having followed Zucara for some time, we are excited to support the further advancement of this promising candidate that has the potential to address a common and potentially life-threatening complication of Type 1 diabetes.'.

评论道：“我们的投资是基于我们的母公司Breakthrough T1D之前对Zucara提供的资金支持，以推动ZT-01的发现和临床开发。在关注Zucara一段时间后，我们很高兴能够支持这一具有潜力的候选药物进一步发展，它有可能解决1型糖尿病常见且可能危及生命的并发症。”

In connection to the Financing, Dr. Tobé will join Zucara as a Board Observer. Dr. Tobé is an experienced biotech industry professional with over a decade of experience in the sector. Prior to joining the T1D Fund, she was a Principal on the investment team at Omega Funds, where she focused on early-stage investments and company creation in various therapeutic areas.

在融资方面，Tobé博士将作为董事会观察员加入Zucara。Tobé博士是一位拥有十多年行业经验的资深生物技术专业人士。在加入T1D基金之前，她是Omega Funds投资团队的负责人，专注于各治疗领域的早期投资和公司创建。

She also previously served at publicly traded Ra Pharmaceuticals, a peptide drug discovery company, where she provided scientific leadership for multiple discovery programs within its internal pipeline and in collaboration with Merck. Dr. Tobé is a Board Director at DiogenX and a Board Observer at various biotech companies across the auto-immune and regenerative spaces..

她还曾在上市的Ra Pharmaceuticals公司任职，这是一家肽类药物研发公司，她为公司内部管线中的多个发现项目以及与默克公司的合作项目提供了科学领导。托贝博士是DiogenX的董事会董事，并在多家横跨自身免疫和再生领域的生物技术公司担任董事会观察员。

Proceeds from the Financing are expected to fund the remainder of Zucara's ongoing Phase 2a trial of the effect of

融资所得款项预计将用于资助Zucara正在进行的2a期试验的剩余部分，该试验研究的是

T-01

北

octurnal hypoglycemia

夜间低血糖

vents in Type 1 diabetes ('T1D') mellitus ('ZONE'), and the nonclinical development of a once-weekly version of ZT-01.

1型糖尿病（'T1D'）事件（'ZONE'），以及ZT-01每周一次版本的非临床开发。

About The T1D Fund

关于T1D基金

The T1D Fund is an impact investment fund focused on accelerating life-changing solutions to treat, prevent, and ultimately cure type 1 diabetes (T1D). Launched in

T1D基金是一个影响力投资基金，专注于加速治疗、预防并最终治愈1型糖尿病（T1D）的变革性解决方案。该基金于

December 2016

2016年12月

, the T1D Fund is a unique, evergreen construct that is the first scaled, mission-driven venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. By partnering with additional sources of capital, including venture capital, corporations, and foundations, the T1D Fund is able to attract and effectively deploy capital towards disease-modifying therapies and potential cures for T1D. Managed by a dedicated team of investment professionals and supported by its foundational partners - including Breakthrough T1D (formerly JDRF) and the Helmsley Charitable Trust, the leading global organizations funding T1D research - the T1D Fund continues to pursue innovative approaches that have the curative potential to make a significant impact for people living with T1D.

T1D基金是一种独特的常青架构，是首个规模化、使命驱动型的风险投资基金，通过股权投资来催化T1D治愈导向疗法的开发。通过与包括风险资本、企业及基金会等其他资本来源合作，T1D基金能够吸引并有效配置资金，用于改变疾病进程的疗法及潜在的T1D治愈方案。该基金由一支专业的投资团队管理，并得到其创始合作伙伴的支持，包括突破性T1D（原JDRF）和赫尔姆斯利慈善信托基金——这些是全球资助T1D研究的领先组织。T1D基金持续追求具有治愈潜力的创新方法，为T1D患者带来重大影响。

For more information, visit .

欲了解更多信息，请访问。

t1dfund.org

or follow the T1D Fund on

或关注T1D基金

领英

。

About ZT-01

关于ZT-01

ZT-01 is designed to prevent potentially dangerous low blood glucose by restoring the body's ability to counterregulate hypoglycemia. In people without diabetes, α-cells secrete glucagon that signals the body to release its own glucose stores to prevent or reverse hypoglycemia. However, in people with insulin-dependent diabetes – including those with T1D and insulin-dependent Type 2 diabetes – evidence suggests that elevated secretion of pancreatic somatostatin suppresses glucagon release from α-cells.

ZT-01旨在通过恢复身体对低血糖的反向调节能力，预防潜在危险的低血糖。在非糖尿病患者中，α细胞分泌的胰高血糖素会信号通知身体释放自身储存的葡萄糖，以预防或逆转低血糖。然而，在依赖胰岛素的糖尿病患者（包括1型糖尿病和依赖胰岛素的2型糖尿病患者）中，有证据表明胰腺生长抑素分泌增加会抑制α细胞释放胰高血糖素。

Zucara has demonstrated that, in people with T1D, the glucagon response can be increased with ZT-01, a first-in-class SST receptor 2 antagonist..

Zucara已经证明，对于1型糖尿病患者，使用ZT-01（一种首创的SST受体2拮抗剂）可以增强胰高血糖素反应。

About Zucara Therapeutics Inc.

关于Zucara Therapeutics公司

Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia in people with T1D and insulin-dependent Type 2 diabetes. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with these conditions.

Zucara Therapeutics正在开发ZT-01，这是一种首创的、每日一次的治疗药物，用于预防1型糖尿病（T1D）和依赖胰岛素的2型糖尿病患者的低血糖。ZT-01旨在抑制生长抑素，这种胰腺激素会削弱这些患者对低血糖的胰高血糖素反应。

ZT-01 is designed to restore glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. For more information, visit .

ZT-01旨在恢复胰高血糖素分泌以预防低血糖，这可能会显著改变糖尿病的管理方式，并改善患者的健康状况和生活质量。欲了解更多信息，请访问。

www.zucara.ca

。

SOURCE Zucara Therapeutics Inc.

来源：Zucara Therapeutics Inc.

WANT YOUR COMPANY'S NEWS

希望贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &